NEW YORK, June 4, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biogen investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 13, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=82 ...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Biogen Inc. (NASDAQ: BIIB)?Did you purchase your shares between February 3, 2022 and February 13, 2024, inclusive?Did you lose money in your investment in Biogen Inc.?Do you want to discuss your rights? Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB ...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and Febru ...

Investors can contact the law firm at no cost to learn more about recovering their losses. LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Biogen Inc. (“Biogen”) (NASDAQ: BIIB) investors who suffered substantial losses to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can pro ...

RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. (“Biogen”) (NASDAQ: BIIB). The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Biogen’s ...

文章核心观点 - 生物医药公司Biogen和航空公司Delta Flight Products将合作,了解残障乘客的出行需求,并开发更加包容和无障碍的航空旅行体验 [1][2][3] - 双方将在Cure SMA 2024年年会上与患有神经肌肉疾病的乘客互动,了解他们的出行需求和痛点,并展示Delta Flight Products研发的可以让乘客使用自己轮椅的座椅原型 [4][5][6] - Biogen长期致力于为罕见神经肌肉疾病患者提供独立生活支持,此次合作是为了推动航空无障碍化 [3] - Delta Flight Products致力于开发创新的航空座椅和舱内设计,其无障碍座椅原型获得2024年APEX创新大奖 [5][9] 公司信息 Biogen - 1978年成立的生物医药公司,专注于开发创新药物,为患者和股东创造价值 [7][8] - 在罕见神经肌肉疾病领域有深厚积累,此次合作是为了推动航空无障碍化 [3] Delta Flight Products - 为航空公司提供创新的机舱设计、技术系统、舱内设备等解决方案 [9] - 研发了可以让残障乘客使用自己轮椅的航空座椅,获得2024年APEX创新大奖 [5][9] 合作内容 - 双方将在Cure SMA 2024年年会上与患有神经肌肉疾病的乘客互动,了解他们的出行需求和痛点 [4][6] - 将利用这些洞见,开发更加包容和无障碍的航空旅行体验 [2][6]

Upcoming community events will inform plans to create more equitable flying experiences for passengers with reduced mobility CAMBRIDGE, Mass. and ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Delta Flight Products (DFP), a wholly-owned subsidiary of Delta Air Lines established to create aircraft interior solutions to airlines around the world, announced that the companies will collaborate to inform future enhancements to the air travel journey for passengers with reduced mobility ...

NEW YORK, May 30, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both dates ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen's third rare disease therapy to be approved in the EU, demonstrating the company's commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) ...